SCHEMBL20158641

SCHEMBL20158641

Cc1ccc(F)cc1NC(=O)C1(C)CCN(C(C)C)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CETP P11597 3/20 0.45
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 3/20 0.43
HTT P42858 1/20 0.43
ABL1 P00519 1/20 0.42
MAPK1 P28482 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RET P07949 1/20 0.41
ALDH1A1 P00352 5/20 0.40
HPGD P15428 2/20 0.40
TSHR P16473 1/20 0.40
KDM4E B2RXH2 3/20 0.39
GAA P10253 1/20 0.39
HSD17B10 Q99714 1/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HDAC4 P56524 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20158644 0.86 CETP (0.47) CETPMEN1KMT2AMAPTHTT
SCHEMBL25504631 0.85 CETP (0.46) CETPMEN1KMT2AMAPTHTT
SCHEMBL20148034 0.83 POLB (0.49) CETPMEN1KMT2AMAPTABL1
SCHEMBL28687087 0.78 NTRK1 (0.52) CETPMEN1KMT2AMAPTMAPK1
SCHEMBL30273016 0.78 NTRK1 (0.52) CETPMEN1KMT2AMAPTMAPK1
SCHEMBL20158642 0.74 OPRM1 (0.46) CETPKMT2ARETALDH1A1
SCHEMBL20147539 0.73 RET (0.46) RET
SCHEMBL20147938 0.72 ALDH1A1 (0.53) CETPHTTMAPK1NPSR1ALDH1A1
SCHEMBL4819210 0.72 MAPK1 (0.55) MEN1KMT2AMAPTHTTMAPK1
SCHEMBL4819221 0.72 MAPK1 (0.55) MEN1KMT2AMAPTHTTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 CETP 4877/4885MEN1 653/4885KMT2A 1112/4885
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 CETP 4877/4885MEN1 653/4885KMT2A 1112/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 CETP 4877/4885MEN1 653/4885KMT2A 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.